Which genetic lung cancer does Osimertinib treat?

Osimertinib is a third-generation TKI designed to target EGFR TKI-sensitizing mutations and T790M while retaining wild-type EGFR. Based on its significant clinical activity and good safety profile in early phase I and phase II trials, osimertinib was first approved by the US FDA in 2015 and approved by the European Medicines Agency in early 2016 for the treatment of patients with EGFR T790M mutation-positive non-small cell lung cancer who have progressed after EGFR TKI treatment.

Recent Phase 3AURA3 trial results demonstrate that osimertinib is superior to standard platinum-based dual chemotherapy in the treatment of patients with advanced non-small cell lung cancerEGFR Patients with T790M mutation-positive non-small cell lung cancer who experience disease progression after first-line EGFR TKI therapy have clearly established third-generation TKIs as the standard of care in this setting. Osimertinib has shown significant clinical activity as a single agent for the first time in patients with EGFR-mutated non-small cell lung cancer with acquired resistance to erlotinib, gefitinib, or afatinib.

OsimertinibThe original drug has been launched in China and has entered the scope of medical insurance. Its name is Osimertinib Mesylate Tablets. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. SpecificationThe price of 80mg*30 tablets per box is around RMB 5,000, which is relatively expensive. The original drug of Osimertinib has also been launched overseas, and there are also generics of Osimertinib produced in other countries. For example, the price of 80mg*30 tablets per box produced by Bangladesh Yaopin International is around RMB 850 (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of the generic Osimertinib and the original drug are basically the same.